AIDXHealthcare · Medical Devices

AIDX Stock Forecast: 20/20 Biolabs, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026

$0.56

+8.13% on the day

The 1 Wall Street analysts covering 20/20 Biolabs, Inc. hold a median 12-month price target of $5 — +799.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap

$6.8M

Ticker Nerd rank

5 / 100

Median analyst target

$5.00

Analysts covering

Total return, dividends reinvested

+1.1%

From high

−97.7%

From low

+39.0%

$24

Range since 19 Feb 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

AIDX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores 20/20 Biolabs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026

5 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Revisions

Value

Growth

Accruals

Quality

Momentum

Issuance

Volatility

Size (95): Smaller than most of the companies we track.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AIDX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AIDX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 19 Feb 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says1 analysts

1 Buy0 Hold0 Sell

Low $5.00Median $5.00High $5.00

The green dot is the last close — the median target sits +799.4% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
11 May 2026	Maxim Group	Initiates	Buy	$5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AIDX appears on the weeks it earns a place.

Estimates

AIDX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

20/20 Biolabs, Inc. (AIDX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −1.6×
Price / sales: 3.8×
Price / book: 1.6×
EV / EBITDA: −0.7×

Growth & margins

Revenue growth (YoY): −36.2%
Earnings growth (YoY): —
Gross margin: 17.8%
Operating margin: −408.4%
Net margin: −279.1%

Returns & dividend

Return on equity: −241.6%
Return on assets: −58.9%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

AIDX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
AIDX20/20 Biolabs, Inc.	$6.8M	5
ICCMIceCure Medical Ltd.	$6.8M	38
NVNOenVVeno Medical Corp.	$6.7M	33
NXLNexalin Technology, Inc.	$7.3M	38
PMIPicard Medical, Inc.	$7.5M	33
CODXCo-Diagnostics, Inc.	$7.6M	37
INBSIntelligent Bio Solutions, Inc.	$7.6M	9

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own 20/20 Biolabs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AIDX news & analysis

20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level

GlobeNewsWire · 17 Aug 2026positive

20/20 BioLabs reported its second quarter 2026 financial and operational results, highlighted by record quarterly OneTest™ revenue of $0.7 million, a 47% year-over-year increase. Gross profit rose 87% to $0.3 million with gross margin expanding to 41.7% from 30.5%, while cash stood at $4.5 million as of June 30, 2026 and all convertible note debt was eliminated during the quarter.

Why it matters — The results show the company's flagship multi-cancer early detection test reaching record quarterly revenue with improved margins and a stronger balance sheet, marking meaningful operational progress for AIDX watchers.

20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management's Recent East Asia Business Development Tour

GlobeNewsWire · 30 July 2026positive

20/20 BioLabs announced it will host an investor webinar on August 5, 2026, led by CEO Jonathan Cohen, to discuss commercial opportunities following management's recent East Asia business development tour, including participation in BIO Asia-Taiwan and strategic meetings in Taipei, Tokyo, and Seoul.

Why it matters — AIDX watchers would care because the webinar may provide insights into potential commercial partnerships and business development efforts in key East Asian markets following management's recent international meetings.

20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy

GlobeNewsWire · 27 July 2026positive

20/20 BioLabs participated in the BIO Asia-Taiwan conference and held meetings with strategic counterparties in Taipei, Tokyo, and Seoul to advance its East Asia roll-up strategy.

Why it matters — The meetings in key East Asian markets indicate that AIDX is actively pursuing its stated roll-up strategy in the region, which could shape the company's expansion trajectory.

FAQ

Frequently asked questions about AIDX stock

What is the AIDX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering 20/20 Biolabs, Inc. have a median 12-month price target of $5, with estimates ranging from $5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AIDX stock a buy right now?

Of the 1 analysts covering 20/20 Biolabs, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks 20/20 Biolabs, Inc. 5 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AIDX?

As at 22 Aug 2026, 20/20 Biolabs, Inc. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

Will AIDX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +799.4% from the last close, and Ticker Nerd's factor model ranks 20/20 Biolabs, Inc. 5 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AIDX stock forecast for 2030?

No analyst covering 20/20 Biolabs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIDX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $5 over the next 12 months.

What does 20/20 Biolabs, Inc. do?

What is the latest news on AIDX?

The most recent item we track (GlobeNewsWire, 17 Aug 2026): "20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level". 20/20 BioLabs reported its second quarter 2026 financial and operational results, highlighted by record quarterly OneTest™ revenue of $0.7 million, a 47% year-over-year increase. Gross profit rose 87% to $0.3 million with gross margin expanding to 41.7% from 30.5%, while cash stood at $4.5 million as of June 30, 2026 and all convertible note debt was eliminated during the quarter.

Company

About 20/20 Biolabs, Inc.

20/20 Biolabs, Inc. is a healthcare diagnostics company that develops and commercializes AI-powered, laboratory-based blood tests focused on early detection and prevention of cancers and chronic diseases. Its core offering is the OneTest for Cancer, a multi-cancer early detection blood test that uses machine learning and proteomic biomarkers to identify risk signals across several malignancies. The company also provides OneTest for Longevity, which measures inflammatory biomarkers to support assessment of long-term health risks, and offers convenient at-home sample collection through upper arm devices designed to avoid traditional needle-based draws. Testing is performed in its CAP-accredited, CLIA-licensed laboratory in Gaithersburg, Maryland, ensuring compliance with clinical laboratory quality standards. In addition, 20/20 Biolabs operates the Clinical Lab Innovation Axcelerator (CLIAx), supporting overseas diagnostics startups with a U.S.-based CLIA lab platform. Its portfolio further includes specialized tests such as PAULA’s Test and the BioCheck suspicious powder testing kit, serving occupational health, safety, and biodefense-related use cases. Founded in 2000 and headquartered in Gaithersburg, Maryland, the company occupies a niche at the intersection of artificial intelligence, proteomics, and clinical diagnostics.

CEO Mr. Jonathan Cohen · 4 employees · United States · https://2020biolabs.com